A record of what Jefferies Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Initiated coverage on Ajanta Pharma with a 'buy' rating, projecting an 11% upside from current levels. This positive outlook suggests a bullish stance on the stock's near-term performance.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
Ajanta Pharma LtdBullishCalled 15 Apr 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Jefferies Analysis’s full track record